A Long Term Study of Molecular and Structural Imaging in Atypical Alzheimer's Disease

Overview

About this study

The purpose of this study is to learn more about amyloid and tau burden in the brain of patients with Atypical Alzheimer's Disease and how that burden may change over a two-year period.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • All enrolled subjects will be over the age of 21.
  • Will have an informant who will be able to provide independent evaluation of functioning.
  • Subjects will only be included if English is their primary language or if they are bilingual.
  • In order to be included in the study all subjects must have insidious onset, report progression of their symptoms, and meet current clinical diagnostic criteria for typical amnestic Alzheimer's Disease (AD) or an atypical AD syndrome.
  • All atypical AD syndromes must present with early and dominant impairments in a cognitive domain that is not memory, including language (verbal and/or written), visuospatial/perceptual function, executive function, working memory, behavioral control, calculation or praxis.
  • All atypical AD subjects must have relative preservation of episodic memory compared to impairment in the non-episodic memory domain. As discussed above, subjects will only be included in the study if they have Aβ deposition on PET imaging, to ensure that all subjects have underlying AD.

Exclusion Criteria:

  • Subjects will be excluded if they do not meet our inclusion criteria or if they have a stroke or tumor that could explain their symptoms.
  • Subjects who present with mild cognitive impairment without evidence of dementia will not be recruited into the study.
  • Subjects who meet specific criteria for another neurodegenerative disorder, including semantic dementia, primary progressive apraxia of speech, or progressive supranuclear palsy, will be excluded.
  • Subjects will not be excluded if they have depression, features of Lewy body disease or behavioral features.
  • Subjects will be excluded if they have poor vision (20/400).
  • Women who are pregnant or post-partum and breast-feeding will be excluded. All women who can become pregnant must have a pregnancy test no more than 48 hours before the PET scan.
  • Subjects will also be excluded if MRI is contraindicated, if there is severe claustrophobia, if there are conditions that may confound brain imaging studies (e.g., structural abnormalities), or if they are medically unstable or are on medications that might affect brain structure or metabolism (e.g., chemotherapy).
  • Subjects will also be excluded if they do not have an informant, or do not consent to research.
  •  

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Jennifer Whitwell, Ph.D.

Open for enrollment

Contact information:

Sarah Boland CCRP

(507)284-3863

Boland.Sarah@mayo.edu

More information

Publications

Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available

.
CLS-20200918

Mayo Clinic Footer